VBI Vaccines Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.00
Dividend & YieldN/A$ (N/A)
Beta 1.82
Market capitalization 144.08M
Operating cash flow -73.17M
ESG Scores unknown

Company description

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio3.92
Working Capital-0.71
Return On Equity-0.48
Debt To Equity0.2
Fixed Asset Ratio0.35
Fixed Interest Cover-13.33

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 8.73M -6.87M 1.29M 28k
Total Cashflows From Investing Activities -5.99M -3.67M -26M 23.16M
Net Borrowings 4.7M 4.7M 4.7M 12M
Total Cash From Financing Activities 43.62M 37.41M 122.39M 44.29M
Change To Operating Activities 4.04M 762k -9.61M 15.62M
Issuance Of Stock 46.62M 40.25M 124.33M 33.38M
Net Income -63.6M -54.81M -46.23M -69.75M
Change In Cash -8.42M -15.06M 49.61M 27.87M
Effect Of Exchange Rate -515k -87k 270k 328k
Total Cash From Operating Activities -45.53M -48.71M -47.05M -39.91M
Depreciation 542k 1.2M 1.65M 1.83M
Change To Account Receivables 79k -136k 130k 69k
Other Cashflows From Financing Activities -3.01M -2.83M -6.63M -1.09M
Change To Netincome 3.78M 10.53M 6.1M 9.8M
Capital Expenditures -5.99M -3.67M -1M -2M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 38.47M 26.33M 14.86M 19.56M
Income Before Tax -63.6M -54.81M -46.23M -69.75M
Net Income -63.6M -54.81M -46.23M -69.75M
Selling General Administrative 20.51M 14.09M 20.65M 38.34M
Gross Profit -1.15M -5.68M -8.11M -10.14M
Ebit -60.13M -46.11M -43.62M -68.03M
Operating Income -60.13M -46.11M -43.62M -68.03M
Interest Expense -3.25M -3.03M -3.32M -5.1M
Income Tax Expense
Total Revenue 3.35M 2.22M 1.06M 631k
Cost Of Revenue 4.51M 7.9M 9.17M 10.77M
Total Other Income ExpenseNet -3.47M -8.71M -2.61M -1.72M
Net Income From Continuing Ops -63.6M -54.81M -46.23M -69.75M
Net Income Applicable To Common Shares -63.6M -54.81M -46.23M -69.75M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 39.47M 33.95M 37.67M 66.39M
Total Stockholder Equity 98.13M 88.25M 171.71M 143.88M
Other Current Liabilities 4.17M 1.27M 1.44M 12.17M
Total Assets 137.6M 122.2M 209.37M 210.28M
Common Stock 246.42M 284.96M 403.53M 442.24M
Other Current Assets 512k 212k 1.31M 2.19M
Retained Earnings -207.57M -262.39M -308.62M -378.37M
Treasury Stock -4.16M -752k 1.26M -1.56M
Cash 59.27M 44.21M 93.83M 121.69M
Total Current Liabilities 23.38M 29.76M 17.35M 32.59M
Other Stockholder Equity -4.16M -752k 1.26M -1.56M
Property, Plant, and Equipment 8.53M 11.65M 12.28M 14.38M
Total Current Assets 61.73M 46.96M 132.04M 130.28M
Net Tangible Assets 31.62M 25.29M 107.29M 79.53M
Net Receivables 56k 439k 7.91M 1.45M
Accounts Payable 6.05M 1.13M 3.73M 4.28M


Insider Transactions

Here are the insider transactions of stock shares related to VBI Vaccines Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Beattie (Nell)Acquisition or disposition in the public market at price 2.45 per share.D2021-12-03Senior Officer of Issuer8.15k
Beattie (Nell)Acquisition or disposition in the public market at price 2.46 per share.D2021-12-03Senior Officer of Issuer50

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to VBI Vaccines Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on VBI Vaccines Inc

Here is the result of two systematic investment strategies applied to VBI Vaccines Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on VBI Vaccines Inc

The following chart shows the equity curve of the two systematic investment strategies applied to VBI Vaccines Inc:

VBI Vaccines Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 78.8% on the backtest period.

Performance at glance

Performance

78.8 %

Latent gain

1774.27 $

Invested capital

2251.73 $

Annualized return

19.03 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on VBI Vaccines Inc

This is the result of two momentum investment strategies applied to VBI Vaccines Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on VBI Vaccines Inc

The following chart shows all the entries opened by the momentum investment system on VBI Vaccines Inc:

VBI Vaccines Inc momentum entries
  • The first momentum investment strategy would give 117.29% of return on VBI Vaccines Inc. That represents 6156.06$ of latent gain with 5248.74$ of employed capital.
  • The second momentum investment strategy would give 89.83% of return on VBI Vaccines Inc. That represents 2918.72$ of latent gain with 3248.98$ of employed capital.
Performance at glance (1Q Momentum)

Performance

117.29 %

Latent gain

6156.06 $

Invested capital

5248.74 $

Annualized return

3.18 %
Performance at glance (2Q Momentum)

Performance

89.83 %

Latent gain

2918.72 $

Invested capital

3248.98 $

Annualized return

24.54 %

Momentum equity curve on VBI Vaccines Inc

The following chart shows the equity curve of the two momentum strategies applied to VBI Vaccines Inc:

VBI Vaccines Inc momentum equity

Note: the dividends potentially given by VBI Vaccines Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VBI Vaccines Inc

The following chart shows the employed capital evolution of the two momentum strategies on VBI Vaccines Inc since the beginning:

VBI Vaccines Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on VBI Vaccines Inc

Buy the dip entry openings on VBI Vaccines Inc

VBI Vaccines Inc

The performance achieved by the robo-advisor on VBI Vaccines Inc is 6.8%. That represents 17.01$ of latent gain with 250.29$ of employed capital. The following chart shows VBI Vaccines Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of VBI Vaccines Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

6.8 %

Latent gain

17.01 $

Invested capital

250.29 $

Annualized return

3.18 %

Equity curve of the strategy applied to VBI Vaccines Inc

The following chart shows the result of the investment strategy applied to VBI Vaccines Inc:

VBI Vaccines Inc

Note: the dividends potentially given by VBI Vaccines Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VBI Vaccines Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on VBI Vaccines Inc:

VBI Vaccines Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on VBI Vaccines Inc

In this section, I will compare the three previous investment strategies applied to VBI Vaccines Inc.

Equity curve comparison on VBI Vaccines Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

VBI Vaccines Inc investment strategy comparison

Employed capital comparison on VBI Vaccines Inc

VBI Vaccines Inc investment comparison

Performance comparison on VBI Vaccines Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 78.8% 1774.27$ 2251.73$ 19.03%
Momentum 1 quarter 117.29% 6156.06$ 5248.74$ 30.07%
Momentum 2 quarters 89.83% 2918.72$ 3248.98$ 24.54%
Non-directional 6.8% 17.01$ 250.29$ 3.18%
Annualized return comparison

Automatic investment

19.03 %

Momentum 1Q

24.54 %

Momentum 2Q

24.54 %

Non-directional

3.18 %

Correlated stocks

Here are the most positively and negatively correlated stocks with VBI Vaccines Inc:

Positive correlations

Most correlated stocks this year

  • VBI Vaccines Inc

  • Most correlated stocks last 3 months

  • VBI Vaccines Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between VBI Vaccines Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of VBI Vaccines Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name VBI Vaccines Inc
    Country United States
    City Cambridge
    Address 160 Second Street
    Phone 617 830 3031
    Website www.vbivaccines.com
    FullTime employees 149
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker VBIV
    Market www.nasdaq.com

    VBI Vaccines Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown